Product Information
XIGDUO XR 10 MG-500 MG TABLET is a brand product labeled by AstraZeneca Pharmaceuticals LP, priced at $19.2391 per EA under NDC 00310627030. Its NADAC has been published 572 times since Oct 21, 2015.
FDA first approved this application on Oct 29, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
10; 500 mg/1; mg/1
Manufacturer
AstraZeneca Pharmaceuticals LPNDC
00310627030
Classification
Brand
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA205649FDA Approved
10/29/2014
TE Code
AB
On Market Since
10/29/2014
Pharmacological Classes
Price Statistics
The NADAC for XIGDUO XR 10 MG-500 MG TABLET has been published 572 times since Oct 21, 2015, and over the history we have for it it has risen 63.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $19.2391 per EA |
|---|---|
| All-time high | $19.2391 (Sep 30, 2026) |
| All-time low | $11.7574 (Oct 21, 2015) |
| 52-week high | $19.2391 |
| 52-week low | $19.2078 |
| Median price | $17.0474 |
| Average price | $16.4991 |
| Largest weekly change | +8.4% (Jan 18, 2017) |
| Weeks tracked | 572 |
| Tracking since | Oct 21, 2015 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the dapagliflozin and metformin hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AstraZeneca Pharmaceuticals LP manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
dapagliflozin and metformin hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Biguanide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of XIGDUO XR 10 MG-500 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for XIGDUO XR 10 MG-500 MG TABLET, manufactured by AstraZeneca Pharmaceuticals LP, is $19.2391 per EA (NDC 00310627030), effective Sep 30, 2026.
How has the price of XIGDUO XR 10 MG-500 MG TABLET changed over time?
Over the history we have for it, the NADAC for XIGDUO XR 10 MG-500 MG TABLET has risen 63.6%. It has been tracked across 572 weekly CMS publications since Oct 21, 2015.
What are the highest and lowest recorded NADAC prices for XIGDUO XR 10 MG-500 MG TABLET?
Since Oct 21, 2015, the NADAC for XIGDUO XR 10 MG-500 MG TABLET has ranged from a low of $11.7574 (Oct 21, 2015) to a high of $19.2391 (Sep 30, 2026), with a median of $17.0474 per EA.
Are there cheaper alternatives to XIGDUO XR 10 MG-500 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of XIGDUO XR 10 MG-500 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures XIGDUO XR 10 MG-500 MG TABLET?
XIGDUO XR 10 MG-500 MG TABLET (NDC 00310627030) is labeled by AstraZeneca Pharmaceuticals LP, and CMS classifies it as a brand product.